ESR1 and breast cancer: To prevent cardiac remodeling, we suggest that ER+ breast cancer patients receiving letrozole should abstain from a carbohydrate-rich diet and medicate with an activator of fatty acid oxidation for facilitating fatty acid oxidation, at least during the letrozole treatment.